Aug. 28, 2013, 7:37 AM
- Astex Pharmaceuticals' (ASTX) SGI-110 "showed clear activity in patients with acute myeloid leukemia" in Phase II testing.
- The overall remission rate in 67 subjects was 25%.
- However, no results were provided for patients with Myelodysplastic syndromes (MDS), a group of blood and bone marrow disorders, who were also part of the trial.
- Shares +12.2%.
Mar. 13, 2012, 9:00 AM
Aug. 12, 2011, 8:54 AM
Midas (MDS) +23.9% premarket after the auto repair and services company announced after yesterday's close that it is exploring strategic alternatives including a possible sale, merger or other business combination.| Aug. 12, 2011, 8:54 AM
Currently, there's no company description for MDS.
Industry: Specialty Retail, Other
Country: United States
Other News & PR